Skip to main content
ZTSZoetis Inc.Sell5.5·$76.30+0.17%

Zoetis (ZTS) Q2 2026 earnings — TrendMatrix coverage

BEAT+0.9% vs estimateEPS $1.87 vs $1.85 estVerdict Buy (Wait)Sell

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$1.87
Estimate
$1.85
Surprise
+0.9%
Revenue (period 2026-06-30)
$2.47B
Score at report (before → after)
6.26.2/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Zoetis (ZTS) beat the $1.85 estimate with diluted EPS of $1.87 — a modest 0.9% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.2/10) to Sell at 6.2/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates ZTS Sell at 5.5/10.

3 of the last 4 quarters beat the estimate; this quarter's +0.9% surprise compares with a +1.5% four-quarter average. Next scheduled report: 2026-11-03.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Geographic: United States (54.0%)
  • Concentration risk — Product: companion animal products (70.0%)
  • Leverage penalty (D/E 2.9): -1.5

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$76.30
Price target
$86.40
Stop
$71.53
Upside to target
+13.2%
Reward-to-risk
1.9:1

At 12.4× trailing and 11.7× forward earnings, consensus estimates imply little change in earnings power.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

ZTS at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Drug Manufacturers - Specialty & Generic
Market cap
$31.52B
P/E (fwd)
11.7
P/E (ttm)
12.4
52-week range
$71.00$155.15
Off 52-week high
50.8%
RSI (14)
58
Volume vs avg
0.57×
Score today
5.5/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks ZTS Earnings Q2 2026 earnings